Playback speed
10 seconds
MV130, a Sublingual Bacterial Immunotherapy to Prevent COPD Exacerbations - Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial
210 views
October 6, 2021
Login to view comments.
Click here to Login